NeoVista's wet age-related macular degeneration device:
This article was originally published in Clinica
Executive Summary
Fremont, California-based NeoVista has CE marked its focal epiretinal brachytherapy device for sale in Europe. The wet age-related macular degeneration (AMD) therapy delivers focused beta radiation - using strontium 90 - to the leaking blood vessels that affect central vision, without causing damage to the surrounding tissues. The company says that preliminary data show it to be safe for both the patient and the physician and may be able to reverse vision loss. NeoVista is currently conducting the final US phase III clinical trial required to gain US approval for the technology.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.